The White House announced accords with nine major drugmakers to lower certain drug prices in Medicaid, extending a ‘most favored nation’ style pricing push across the supply chain. Companies involved include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. Officials said the agreements cover pricing parity measures for drugs sold in the U.S. relative to peer nations. Administration officials described the package as the largest batch of pricing deals to date; company-level commitments will affect an estimated 30–40% of Medicaid drugs. The policy direction follows earlier rounds of negotiations and raises questions about commercial contracting, global reference pricing, and manufacturer revenue impact. Biopharma executives and investor groups will watch implementation and contract mechanics closely; legal and operational changes at manufacturers and payers may follow as the deals are operationalized.